Best Vyxeos (Daunorubicin/Cytarabine) Medicine in India

Vyxeos (Daunorubicin/Cytarabine) is an anticancer treatment used to treat adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). It combines two chemotherapy medicines, daunorubicin and cytarabine, to help destroy abnormal leukemia cells and control the growth of the disease.

Vyxeos (Daunorubicin/Cytarabine) is administered as an intravenous infusion by a qualified healthcare professional according to the treatment schedule prescribed by the doctor. The treatment is given under close medical supervision, and regular blood tests are performed to monitor blood cell counts, liver and kidney function, and treatment response. Do not miss scheduled appointments or change the treatment schedule without medical advice.

Common side effects of Vyxeos (Daunorubicin/Cytarabine) may include low blood cell counts, fever, nausea, diarrhea, constipation, mouth sores, rash, fatigue, swelling, and headache. The treatment can also cause serious infections, bleeding, heart problems, or infusion-related reactions. Inform your doctor promptly if you develop fever, unusual bleeding, difficulty breathing, chest pain, or other severe or persistent symptoms.

Treatment of Acute Myeloid Leukemia

Vyxeos (Daunorubicin/Cytarabine) is used to treat adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). It combines daunorubicin and cytarabine to destroy abnormal leukemia cells, helping reduce the number of cancer cells and control disease progression.

Most side effects do not require medical attention and may improve as your body adjusts to the treatment. Consult your doctor if they persist, become severe, or cause concern.

Common Side Effects of Vyxeos (Daunorubicin/Cytarabine)

Vyxeos (Daunorubicin/Cytarabine) is given as an intravenous infusion by a qualified healthcare professional according to the treatment schedule prescribed by your doctor. The treatment is administered under close medical supervision, with regular blood tests to monitor blood cell counts, kidney and liver function, and treatment response. Do not change the treatment schedule or miss appointments without consulting your doctor.

Vyxeos (Daunorubicin/Cytarabine) combines daunorubicin and cytarabine in a fixed combination designed to deliver both medicines to leukemia cells. Daunorubicin interferes with DNA replication and damages cancer-cell DNA, while cytarabine blocks DNA synthesis. Together, they prevent leukemia cells from growing and dividing, leading to their destruction.

• Store unreconstituted Vyxeos vials refrigerated between 2°C and 8°C.
• Keep the vials upright in their original carton to protect them from light.
• After reconstitution, use the solution immediately; if necessary, it may be refrigerated at 2°C to 8°C for up to 4 hours.
• If the reconstituted product has already been refrigerated for 4 hours, use the diluted infusion solution immediately and do not store it for an additional 4 hours.

Alcohol CONSULT YOUR DOCTOR

Avoid or limit alcohol during treatment unless your doctor advises otherwise, as it may worsen nausea, fatigue, or other side effects.

Pregnancy CONSULT YOUR DOCTOR

Vyxeos may harm an unborn baby. Inform your doctor if you are pregnant, planning to become pregnant, or could become pregnant. Use effective contraception as advised by your doctor.

Breastfeeding CONSULT YOUR DOCTOR

Do not breastfeed during treatment with Vyxeos and for the recommended period after the final dose, as advised by your healthcare professional.

Driving CONSULT YOUR DOCTOR

Vyxeos may cause dizziness, fatigue, or weakness. Avoid driving or operating machinery if you feel affected.

Kidney CAUTION

Inform your doctor if you have kidney problems. Your kidney function may be monitored during treatment, and your doctor will determine the appropriate treatment plan.

Liver CAUTION

Tell your doctor if you have liver disease. Liver function may be monitored during treatment, and your doctor may adjust treatment if necessary.

• Attend all scheduled Vyxeos (Daunorubicin/Cytarabine) infusions and follow your doctor's treatment schedule carefully.
• Attend regular blood tests to monitor blood cell counts, liver function, kidney function, and treatment response.
• Report fever, chills, unusual bleeding, bruising, or signs of infection promptly to your doctor.
• Inform your doctor about all medicines, supplements, and herbal products you are taking before starting treatment.
• Report chest pain, difficulty breathing, severe weakness, or swelling promptly, as these may require immediate medical attention.
• Read More About - Vyxeos (Daunorubicin/Cytarabine) from Pharma Five.

Pharma Five, may facilitate patients in importing Vyxeos (Daunorubicin/Cytarabine) in small quantities for personal medical use. To proceed with the import, the applicant is required to submit an application in Form 12A along with a prescription issued by a Registered Medical Practitioner (RMP).

Pharma Five offers professional pharmaceutical consultancy and facilitation to help patients access Vyxeos (Daunorubicin/Cytarabine) and other specialized medicines through the relevant import procedures. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.